Compare Enveric Biosciences Inc (ENVB) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while USA Rare Earth Inc. Class A Common Stock trades at $10.02 (market cap $4.23B). The key difference: USA Rare Earth Inc. Class A Common Stock is far larger — about 674.6× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (100,675 versus 13,677,660). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| ENVB | USAR | |
|---|---|---|
Market Cap | $6.27M | $4.23B |
Volume | 100,675 | 13,677,660 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $33.68 |
52-Week Low | $1.27 | $10.32 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $2.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
